Former chairman leaves MassBio a better place
Michael D. Webb, past chairman of the MassBio Board of Directors, has stepped down after a decade of invaluable service to both the organization and the Commonwealth’s life sciences industry.
Webb joined the MassBio board in 2000 and served as chairman from 2006-08. He stayed on as immediate past chairman until March of this year when Geoffrey Cox was elected chairman and Mark Leuchtenberger assumed the position of immediate past chairman. Webb officially departed from his board seat on Sept. 16.
“Mike led MassBio through some challenging times,” said MassBio President & CEO Robert K. Coughlin. “We’re in a better place as an industry and as an organization due to his keen business sense and ability to drill down, reach consensus and solve complicated issues.”
Webb, who has more than 25 years of experience in healthcare and life sciences, serves as executive chairman of Virtify, Inc., a provider of software solutions for regulatory compliance to life sciences companies. He is a founder and on the board of directors of Anchor Therapeutics (formerly Ascent Therapeutics), a venture-backed company focusing on oncology and inflammation treatments. Prior to founding Anchor, he served as CEO of EPIX Pharmaceuticals, Inc. from 1994 through 2005. During this period, EPIX grew from a venture-backed startup to the world leader in discovery and development of pharmaceuticals for imaging with MRI, achieving worldwide approval for its lead product.
A Sherborn resident, Webb currently serves on the boards of Wolfe Laboratories, the Kellogg Center for Biotechnology at Northwestern and the University of Kansas Institute for Advancing Medical Innovation. He also serves as a managing director of Exponential Pharma Ventures and is a senior advisor to Johnston Blakely & Company, a life sciences investment banking firm.